KIT and osteogenesis imperfecta: Although prenatal therapies targeting diseases of hematopoiesis would utilize cKit+/Lin− AFSCs, cKit− amniotic fluid‐derived mesenchymal stem cells (AFMSC) could be utilized for in utero treatment of inherited disorders such as osteogenesis imperfecta 20, 23, 35.